MARKSANS logo

Marksans Pharma Limited Stock Price

NSEI:MARKSANS Community·₹76.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 31 Fair Values set on narratives written by author

MARKSANS Share Price Performance

₹169.46
-117.39 (-40.92%)
26.9% undervalued intrinsic discount
₹231.67
Fair Value
₹169.46
-117.39 (-40.92%)
26.9% undervalued intrinsic discount
₹231.67
Fair Value
Price ₹169.46
AnalystConsensusTarget ₹231.67

MARKSANS Community Narratives

AnalystConsensusTarget·
Fair Value ₹231.67 26.9% undervalued intrinsic discount

Developed Markets Will Support Affordable Generic Expansion

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative

Recent MARKSANS News & Updates

Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

Marksans Pharma Limited Key Details

₹26.5b

Revenue

₹12.0b

Cost of Revenue

₹14.5b

Gross Profit

₹11.0b

Other Expenses

₹3.5b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
7.73
Gross Margin
54.82%
Net Profit Margin
13.20%
Debt/Equity Ratio
12.9%

Marksans Pharma Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Very undervalued with excellent balance sheet.

1 Risk
5 Rewards

About MARKSANS

Founded
1992
Employees
1840
CEO
Mark Saldanha
WebsiteView website
marksanspharma.com

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Indian Market Performance

  • 7 Days: 1.1%
  • 3 Months: -0.1%
  • 1 Year: -4.4%
  • Year to Date: 1.3%
Over the last 7 days, the market has remained flat, although notably the Information Technology sector gained 3.3% in that time. Unfortunately though, the market is down 4.9% over the past year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›